Key Highlights

  • Forte Biosciences shares surged approximately 38.8% in pre-market trading to $76.02, up from a prior close of $54.78.
  • argenx agreed to acquire Forte Biosciences for $77.00 per share in cash, valuing the deal at approximately $2.2 billion.
  • The offer represents a premium of approximately 86% to Forte's volume-weighted average price since it reported positive Phase 1b vitiligo data on July 9.
  • The acquisition adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline, with the deal expected to close in the third quarter of 2026.

argenx to Acquire Immunology Biotech at Steep Premium

Forte Biosciences, Inc. (NASDAQ:FBRX) shares jumped sharply in pre-market trading after argenx (Euronext & Nasdaq:ARGX) announced a definitive agreement to acquire the company for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. The offer reflects a premium of roughly 86% to Forte's volume-weighted average share price since the company reported positive Phase 1b data in vitiligo on July 9.

Forte Biosciences is a clinical-stage biopharmaceutical company headquartered in Dallas, Texas, focused on developing novel therapies for autoimmune and autoimmune-related diseases. Its lead product candidate, FB102, is a proprietary anti-CD122 monoclonal antibody designed to target immune pathways implicated in conditions including celiac disease, vitiligo, alopecia areata, graft-versus-host disease and type 1 diabetes.

The acquisition builds on argenx's prior strategic investment in Forte Biosciences and reflects the company's stated approach of accessing novel biology capable of fueling long-term growth. FB102's Phase 1b studies in vitiligo and celiac disease validated the CD122 mechanism and its potential as a pipeline-in-a-product opportunity, with Forte recently reporting statistically significant treatment benefit in vitiligo and Phase 2 celiac disease data expected in the second half of 2026.

Deal Structure and Strategic Rationale

Under the terms of the agreement, argenx will commence a cash tender offer through a wholly owned subsidiary to acquire all outstanding Forte Biosciences shares, with the transaction not subject to a financing condition and funded entirely from cash on hand. FB102 will complement argenx's existing portfolio of antibody-based programs, including efgartigimod, empasiprubart and adimanebart, by adding a mechanism focused on pathogenic T-cell and NK-cell activity.

Forte Biosciences shares traded at $76.02 in pre-market activity, up from a previous close of $54.78, with a prior-session range between $54.64 and $60.40. The company's market capitalization stood near $1.12 billion prior to the announcement. Goldman Sachs International is serving as exclusive financial advisor to argenx, while Guggenheim Securities is advising Forte Biosciences on the transaction, which has been approved by both companies' boards of directors and remains subject to customary closing conditions, including antitrust clearance.

Conclusion

Forte Biosciences' sharp pre-market gain reflects the substantial premium argenx is paying to secure a clinically validated, first-in-class immunology asset. Investors are likely to watch for the commencement of the tender offer and progress toward the deal's expected close in the third quarter of 2026.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.